Spyre Therapeutics 将来の成長

Future 基準チェック /06

Spyre Therapeutics の収益は、年間 17.2% 減少すると予測されています。EPS は、年間減少すると予測されています7.6%。

主要情報

-17.2%

収益成長率

-7.6%

EPS成長率

Biotechs 収益成長	27.4%
収益成長率	n/a
将来の株主資本利益率	n/a
アナリストカバレッジ	Good
最終更新日	04 Mar 2025

今後の成長に関する最新情報

Recent updates

Spyre Therapeutics: Targeting The Future Of IBD Treatment

Mar 04

Spyre Therapeutics: Different Name, Same Tune

Dec 12

Spyre: Extended Half-Life Tech To Become Differentiating Factor For IBD Targeting

Oct 01

Aeglea BioTherapeutics (NASDAQ:AGLE) Will Have To Spend Its Cash Wisely

Feb 24

We're A Little Worried About Aeglea BioTherapeutics' (NASDAQ:AGLE) Cash Burn Rate

Oct 28

Aeglea stock jumps ~58% after hours on European nod for enzyme pegzilarginase

Aug 18

Aeglea BioTherapeutics GAAP EPS of -$0.27 beats by $0.04, revenue of $0.63M misses by $0.08M

Aug 04

Can Aeglea BioTherapeutics (NASDAQ:AGLE) Afford To Invest In Growth?

Jun 09

Aeglea Presents Itself As Buy Opportunity After Latest Data Causes Stock To Trade Lower

Dec 07

Industry Analysts Just Made A Stunning Upgrade To Their Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) Revenue Forecasts

Aug 10

Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) Just Reported Second-Quarter Earnings And Analysts Are Lifting Their Estimates

Aug 08

業績と収益の成長予測

NasdaqGS:SYRE - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2027	N/A	-300	-238	-241	5
12/31/2026	N/A	-256	-218	-227	8
12/31/2025	N/A	-218	-189	-179	8
12/31/2024	N/A	-150	-157	-157	N/A
9/30/2024	N/A	-215	-151	-151	N/A
6/30/2024	N/A	-186	-141	-156	N/A
3/31/2024	1	-364	-96	-111	N/A
12/31/2023	1	-95	-85	-100	N/A
9/30/2023	1	-294	-72	-87	N/A
6/30/2023	1	-273	-67	-67	N/A
3/31/2023	1	-78	-72	-72	N/A
12/31/2022	2	-84	-80	-80	N/A
9/30/2022	6	-85	-81	-81	N/A
6/30/2022	7	-88	-83	-83	N/A
3/31/2022	20	-72	-61	-60	N/A
12/31/2021	19	-66	-54	-54	N/A
9/30/2021	15	-68	-53	-52	N/A
6/30/2021	14	-66	-54	-52	N/A
3/31/2021	N/A	-80	-77	-74	N/A
12/31/2020	N/A	-81	-80	-76	N/A
9/30/2020	N/A	-80	-79	-75	N/A
6/30/2020	N/A	-83	-79	-75	N/A
3/31/2020	N/A	-80	-74	-72	N/A
12/31/2019	N/A	-78	-67	-66	N/A
9/30/2019	N/A	-72	-57	-57	N/A
6/30/2019	N/A	-62	-48	-48	N/A
3/31/2019	2	-53	-41	-41	N/A
12/31/2018	4	-44	-33	-32	N/A
9/30/2018	5	-36	N/A	-31	N/A
6/30/2018	7	-32	N/A	-30	N/A
3/31/2018	6	-29	N/A	-27	N/A
12/31/2017	5	-27	N/A	-25	N/A
9/30/2017	5	-26	N/A	-23	N/A
6/30/2017	5	-25	N/A	-22	N/A
3/31/2017	5	-23	N/A	-20	N/A
12/31/2016	5	-22	N/A	-19	N/A
9/30/2016	5	-20	N/A	-15	N/A
6/30/2016	5	-17	N/A	-13	N/A
3/31/2016	7	-13	N/A	-12	N/A
12/31/2015	6	-12	N/A	-11	N/A
9/30/2015	5	-11	N/A	-13	N/A
6/30/2015	3	-11	N/A	-11	N/A
3/31/2015	N/A	-12	N/A	-8	N/A

アナリストによる今後の成長予測

収入対貯蓄率: SYRE今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: SYRE今後 3 年間、利益が出ない状態が続くと予測されています。

高成長収益: SYRE今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: SYREの収益がUS市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。

高い収益成長: SYRE来年は収益がないと予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: SYREの自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

成長企業の発掘

企業分析と財務データの現状

データ	最終更新日（UTC時間）
企業分析	2025/03/17 13:29
終値	2025/03/14 00:00
収益	2024/12/31
年間収益	2024/12/31

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージ	データ	タイムフレーム	米国ソース例
会社財務	10年	損益計算書キャッシュ・フロー計算書貸借対照表	SECフォーム10-K SECフォーム10-Q
アナリストのコンセンサス予想	+プラス3年	予想財務アナリストの目標株価	アナリストリサーチレポート Blue Matrix
市場価格	30年	株価配当、分割、措置	ICEマーケットデータ SECフォームS-1
所有権	10年	トップ株主インサイダー取引	SECフォーム4 SECフォーム13D
マネジメント	10年	リーダーシップ・チーム取締役会	SECフォーム10-K SECフォームDEF 14A
主な進展	10年	会社からのお知らせ	SECフォーム8-K

* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用^。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。

分析モデルとスノーフレーク

このレポートの作成に使用した分析モデルの詳細は、Githubページでご覧いただけます。また、レポートの使用方法に関するガイドや、Youtubeでのチュートリアルもご用意しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

Spyre Therapeutics, Inc. 8 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、。アナリストの投稿は一日中更新されます。16

アナリスト	機関
Colleen Kusy	Baird
Mayur Somaiya	BMO Capital Markets Equity Research
Julian Harrison	BTIG

Spyre Therapeutics 将来の成長

Future 基準チェック /06

主要情報

今後の成長に関する最新情報

Consensus revenue estimates increase by 48%

Price target increased by 20% to US$3.12

Consensus EPS estimates upgraded to US$0.61 loss

Price target decreased by 16% to US$2.27

No longer forecast to breakeven

Price target increased to US$2.70

Recent updates

Spyre Therapeutics: Targeting The Future Of IBD Treatment

Spyre Therapeutics: Different Name, Same Tune

Spyre Therapeutics Announces First Participants Dosed in Phase 1 Trials of Novel Half-Life Extended Anti-Tl1a Antibodies

Spyre Therapeutics, Inc. has completed a Follow-on Equity Offering.

Spyre Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $200 million.

Spyre Therapeutics, Inc. Announces Positive Interim Phase 1 Data from its First-In-Human Trial of SPY001

Spyre: Extended Half-Life Tech To Become Differentiating Factor For IBD Targeting

Spyre Therapeutics Appoints Dr. Sheldon Sloan as Chief Medical Officer

Spyre Therapeutics, Inc. Announces First Participants Dose in Phase 1 Trial of SPY001

Spyre Therapeutics, Inc. Announces Board Changes

Spyre Therapeutics, Inc., Annual General Meeting, May 13, 2024

Spyre Therapeutics, Inc. announced that it expects to receive $180.005 million in funding from a group of investors

Spyre Therapeutics, Inc. Announces Board Changes

Spyre Therapeutics, Inc. Announces Board Changes

Spyre Therapeutics, Inc. announced that it has received $180 million in funding from a group of investors

Spyre Therapeutics, Inc. announced that it expects to receive $180 million in funding from a group of investors

Spyre Therapeutics, Inc.(NasdaqCM:SYRE) dropped from NASDAQ Composite Index

Aeglea BioTherapeutics, Inc. Announces Appointment of Cameron Turtle as Principal Executive Officer

Aeglea Biotherapeutics, Inc. Regains Compliance with Nasdaq Listing Rule

Aeglea Biotherapeutics Expands Executive Leadership Team with Appointment of Industry Veterans Scott Burrows and Heidy Abreu King-Jones

Immedica Pharma signed an agreement to acquire global rights to pegzilarginase from Aeglea BioTherapeutics, Inc from Aeglea BioTherapeutics, Inc. (NasdaqCM:AGLE) for $115 million.

Aeglea Biotherapeutics Receives Approval from Nasdaq of the Transfer of the Listing of Its Common Stock from Nasdaq Global Market to the Nasdaq Capital Market

High number of new directors

Aeglea BioTherapeutics, Inc. announced that it expects to receive $210.000248 million in funding from a group of investors

Aeglea BioTherapeutics, Inc. (NasdaqGM:AGLE) acquired Spyre Therapeutics, Inc. for $1.42 million.

New major risk - Share price stability

Aeglea Biotherapeutics, Inc. Announces the Termination of Jeffrey Goldberg as Chief Executive Officer

Aeglea BioTherapeutics, Inc. Announces Executive Changes

Consensus revenue estimates increase by 48%

Price target increased by 20% to US$3.12

Consensus EPS estimates upgraded to US$0.61 loss

Price target decreased by 16% to US$2.27

No longer forecast to breakeven

Aeglea BioTherapeutics (NASDAQ:AGLE) Will Have To Spend Its Cash Wisely

Aeglea BioTherapeutics Receives Written Notice from The Nasdaq Stock Market, LLC Regarding Minimum Bid Price Requirement for Continued Listing

Aeglea Biotherapeutics, Inc. Announces Resignation of Leslie Sloan as Chief Operating Officer

Aeglea Biotherapeutics, Inc. Announces Chief Executive Officer Changes

Aeglea BioTherapeutics, Inc. Appoints Linda Neuman as Chief Medical Officer

Price target increased to US$2.70

Consensus forecasts updated

Price target increased to US$2.70

We're A Little Worried About Aeglea BioTherapeutics' (NASDAQ:AGLE) Cash Burn Rate

Aeglea BioTherapeutics, Inc. Provides Clinical Progress and Regulatory Update for Homocystinuria Program

Insider recently bought US$50k worth of stock

Aeglea Biotherapeutics Announces Leadership Transition

Aeglea BioTherapeutics, Inc. Announces European Medicines Agency Validation of Marketing Authorization Application for Pegzilarginase for the Treatment of Arginase 1 Deficiency

Aeglea stock jumps ~58% after hours on European nod for enzyme pegzilarginase

Consensus forecasts updated

Aeglea BioTherapeutics GAAP EPS of -$0.27 beats by $0.04, revenue of $0.63M misses by $0.08M

Aeglea BioTherapeutics Receives Non-Compliance Notice from Nasdaq

Aeglea BioTherapeutics Announces Resignation of Sandesh Mahatme as Director

Aeglea BioTherapeutics, Inc.(NasdaqGM:AGLE) dropped from Russell 2000 Dynamic Index

Can Aeglea BioTherapeutics (NASDAQ:AGLE) Afford To Invest In Growth?

Aeglea Biotherapeutics, Inc. Receives Refusal to File Letter from FDA for Pegzilarginase for the Treatment of Arginase 1 Deficiency

Consensus revenue estimates increase by 36%

Price target decreased to US$9.86

Price target decreased to US$11.00

Aeglea BioTherapeutics, Inc. Submits BLA to FDA for Pegzilarginase for the Treatment of Arginase 1 Deficiency

Aeglea BioTherapeutics, Inc. Presents Additional Data from PEACE Phase 3 Study of Pegzilarginase for the Treatment of Arginase 1 Deficiency at SIMD

Consensus revenue estimates increase by 76%

President recently bought US$281k worth of stock

Consensus forecasts updated

Price target decreased to US$11.00

Aeglea Biotherapeutics, Inc. Announces Resignation of Sara Brownstein as Class I Director of the Board

Independent Director recently bought US$550k worth of stock

Aeglea BioTherapeutics, Inc. Announces Achievement of Primary Endpoint in Phase 3 Study of Pegzilarginase in Patients with Arginase 1 Deficiency

Price target decreased to US$12.43

Aeglea Presents Itself As Buy Opportunity After Latest Data Causes Stock To Trade Lower

Chief Financial Officer recently bought US$263k worth of stock